Since the early 2000s, health authorities worldwide have documented new, considerable, viral outbreaks every other year on average. While in some cases the epidemic spread was contained within the source of origin country, in other cases, a global outbreak followed, threatening the lives of billions as well as the stability of the global economy. One solution for these epidemics as means of prevention are vaccines which are unavailable in the case of unknown viral agents. Therefore, other solutions are in need to provide immediate treatment for severe illnesses as well as prevent further infections. One such solution is Passive Antibody Therapy where serum-derived viral-neutralizing antibodies from recovering patients are collected and infused into patients in severe condition. This is currently the sole available therapy, providing essential short-term protection, symptoms alleviation and recovery time shortening. For preventative purposes, this therapy can be administered to at-risk populations and medical staff, allowing them to continue their critical functions as healthcare providers. Yet, this method in its current production status bears some significant shortcomings, including limited doses availability, lack of reproducibility and varying therapy efficacy. Therefore, a technology capable of rapidly detect antibody secreting cells from patients, and retrieve their antibody encoding mRNAs is needed. OneCell's unique technology for multi-parametric analysis at single cell resolution, can capture thousands of cells, separately immune-phenotype/characterize each cell and provide the RNA sequence of the desired antibodies capable of neutralizing the virus. With turnaround time of 36 hours from sample to sequence and unmatched cells capturing yield our technology is the ideal tool for rapid identification of anti-viral neutralizing antibodies therapy.
